ArticleScience progress
Relationship between androgen receptor and epidermal growth factor receptor determines aggressive behavior of cutaneous basal cell carcinoma.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveCutaneous basal cell carcinoma (BCC) exhibits numerous variants, ranging from non-aggressive to aggressive behavior. Androgen receptor (AR) and epidermal growth factor receptor (EGFR) are both expressed by BCC. This study aims to analyze the differences between aggressive and non-aggressive variants concerning AR and EGFR expression, as well as their relationship with each other.MethodsBetween 2019 and 2024, we analyzed all archival tissue blocks of patients with a diagnosis of BCC who underwent excision. Fifty-three cases with a diagnosis of superficial, nodular, infiltrative, and micronodular BCC were included in the study. Histologically, the infiltrative and micronodular variants were classified as highly aggressive; nodular and superficial variants less aggressive. These characteristics were compared with other features with respect to their statistical significance.ResultWe found a statistically significant relationship between AR, EGFR expression, and tumor variants. While the AR expression was high in superficial and nodular variants, it was weak in the infiltrative type. Whereas the EGFR expression, contrary to AR, was strong in infiltrative and micronodular variants, it was weak in nodular and superficial variants. There was a statistically significant reverse correlation between AR and EGFR (p = 0.005).ConclusionsThe AR expression in BCC is consistent with low-degree malignancy; conversely, EGFR expression is consistent with aggressiveness. We hope our findings lead to further discoveries in employing topical agents that activate AR, next to anti-EGFR agents. Our study is the first and only one that investigated BCC concerning morphological variants and their relationship with AR and EGFR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.